Marker Therapeutics (MRKR) Accumulated Expenses (2013 - 2023)

Marker Therapeutics (MRKR) has 8 years of Accumulated Expenses data on file, last reported at $610000.0 in Q2 2023.

• Accumulated Expenses for Q2 2023 came in at $610000.0, down 61.02% year-over-year; the trailing twelve-month figure through Jun 2023 was $610000.0 (down 61.02% YoY), and the FY2022 annual result was $750000.0, down 68.75% from the prior year.
• Accumulated Expenses rose to $610000.0 in Q2 2023 per MRKR's latest filing, from $454000.0 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $2.4 million in Q3 2021 and troughed at $323000.0 in Q4 2019.
• A 5-year average of $1.2 million and a median of $858000.0 in 2020 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2020 and 2022: Accumulated Expenses jumped 424.46% in 2020, then sank 68.75% in 2022.
• A 5-year view of Accumulated Expenses shows it stood at $323000.0 in 2019, then jumped by 424.46% to $1.7 million in 2020, then surged by 41.68% to $2.4 million in 2021, then slumped by 68.75% to $750000.0 in 2022, then dropped by 18.67% to $610000.0 in 2023.
• Business Quant data shows MRKR's Accumulated Expenses at $610000.0 in Q2 2023, $454000.0 in Q1 2023, and $750000.0 in Q4 2022.